Gentibio, Inc. secured a $1,150,749 NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
Amount Raised
$1.15 Million
Round Type
Grant
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
ABSTRACT In the U.S., nearly 800,000 individuals experience a stroke each year, predominantly ischemic strokes. The economic burden of stroke is staggering, with projected stroke-related medical costs in the U.S. expected to surpass $94 billion by 2035. This underscores the urgent need for effective therapies to address this significant public health challenge
Quick answer
GentiBio raised $1.15 Million in a Grant round, dated August 2, 2026. Investors: National Institutes Of Health. GentiBio is based in Cambridge, Massachusetts, United States.
- How much did GentiBio raise?
- GentiBio raised $1.15 Million in a Grant round on August 2, 2026.
- Who invested in GentiBio?
- National Institutes Of Health is named as investors in this round.
- What does GentiBio do?
- GentiBio is a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases.
- Where is GentiBio based and how big is it?
- GentiBio is based in Cambridge, Massachusetts, United States. Fundz records about 59 employees.
- Who are the decision-makers at GentiBio?
- Fundz holds 2 contacts at GentiBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as GentiBio that raised within 45 days of this round, from Fundz verified event records.
- Amani Therapeutics raised $35M on September 16, 2026.
- Aitiologic raised $7.4M (Seed) on September 15, 2026.
- Orvida Pharma raised an undisclosed amount on September 15, 2026.
- Tyra Biosciences raised $200M (Funding Round) on September 15, 2026.
- FibroBiologics raised $1M on September 15, 2026.
- Biophytis raised $2.6M (Seed) on September 15, 2026.
Who to call at GentiBio, and when
A new round usually means GentiBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GentiBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GentiBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GentiBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GentiBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
GentiBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.